Related references
Note: Only part of the references are listed.Aurora kinase inhibitor tozasertib suppresses mast cell activation in vitro and in vivo
Li-Na Zhang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells
Jingqiu Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
Zhuo-Xun Wu et al.
CANCERS (2020)
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Karol Bukowski et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells
Zhuo-Xun Wu et al.
FRONTIERS IN ONCOLOGY (2020)
Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells
Zhuo-Xun Wu et al.
CANCER SCIENCE (2020)
Overcoming Multidrug Resistance: Flavonoid and Terpenoid Nitrogen-Containing Derivatives as ABC Transporter Modulators
Bruno M. F. Goncalves et al.
MOLECULES (2020)
Structural insight into substrate and inhibitor discrimination by human P-glycoprotein
Amer Alam et al.
SCIENCE (2019)
Synthesis and Evaluation of Dibenzothiophene Analogues as Pin1 Inhibitors for Cervical Cancer Therapy
Ke-Jia Wu et al.
ACS OMEGA (2019)
Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells
Zhuo-Xun Wu et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Reversible inhibition of efflux transporters by hydrogel microdevices
Elizabeth S. Levy et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2019)
Drug resistance and combating drug resistance in cancer
Xuan Wang et al.
CANCER DRUG RESISTANCE (2019)
Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines
Chung-Pu Wu et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Beyond Competitive Inhibition: Regulation of ABC Transporters by Kinases and Protein-Protein Interactions as Potential Mechanisms of Drug-Drug Interactions
Rebecca R. Crawford et al.
DRUG METABOLISM AND DISPOSITION (2018)
Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia
Raquel C. Maia et al.
MOLECULES (2018)
Structure and Function of Multidrug Resistance Protein 1
E. N. Yakusheva et al.
BIOCHEMISTRY-MOSCOW (2018)
Drug resistance in multiple myeloma
Pawel Robak et al.
CANCER TREATMENT REVIEWS (2018)
Ulixertinib (BVD-523) antagonizes ABCB1-and ABCG2-mediated chemotherapeutic drug resistance
Ning Ji et al.
BIOCHEMICAL PHARMACOLOGY (2018)
A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies
Ankit C. Borisa et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Structure-function relationships in ABCG2: insights from molecular dynamics simulations and molecular docking studies
Ricardo J. Ferreira et al.
SCIENTIFIC REPORTS (2017)
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Behzad Mansoori et al.
ADVANCED PHARMACEUTICAL BULLETIN (2017)
A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors
Manik Amin et al.
INVESTIGATIONAL NEW DRUGS (2016)
Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies
Wen Li et al.
DRUG RESISTANCE UPDATES (2016)
Structural and Pharmacological Studies of an ABC Multidrug Transporter
Tomohiro Yamaguchi
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN (2016)
ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines
Takaaki Oba et al.
ONCOTARGET (2016)
Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1
Chung-Pu Wu et al.
MOLECULAR PHARMACEUTICS (2015)
Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress
Gerald S. Falchook et al.
SEMINARS IN ONCOLOGY (2015)
Selective Targeting of CTNBB1-, KRAS-or MYC-Driven Cell Growth by Combinations of Existing Drugs
Joost C. M. Uitdehaag et al.
PLOS ONE (2015)
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr et al.
CANCER CELL (2014)
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia
Antonino Maria Sparta et al.
CELL CYCLE (2014)
Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances
Evanthia Lionta et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2014)
Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
E. Tavanti et al.
BRITISH JOURNAL OF CANCER (2013)
Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA
Serena Marchetti et al.
INVESTIGATIONAL NEW DRUGS (2013)
ABCB1 Structural Models, Molecular Docking, and Synthesis of New Oxadiazolothiazin-3-one Inhibitors
Camillo Rosano et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Enhancing Chemosensitivity in ABCB1-and ABCG2-Overexpressing Cells and Cancer Stem-like Cells by An Aurora Kinase Inhibitor CCT129202
Chao Cheng et al.
MOLECULAR PHARMACEUTICS (2012)
Software News and Update AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading
Oleg Trott et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2010)
Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C Kinase
Nicholas D. Adams et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
C. Hegedus et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models
Mary Ann Hardwicke et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Aurora C is directly associated with Survivin and required for cytokinesis
XM Yan et al.
GENES TO CELLS (2005)
Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells
K Sasai et al.
CELL MOTILITY AND THE CYTOSKELETON (2004)
The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint
S Hauf et al.
JOURNAL OF CELL BIOLOGY (2003)
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
FX Mahon et al.
BLOOD (2003)
Share Paper
